Cantor Fitzgerald reissued their overweight rating on shares of Exagen (NASDAQ:XGN - Free Report) in a research note released on Monday,Benzinga reports. They currently have a $8.00 price target on the stock.
Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group increased their price target on shares of Exagen from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. William Blair reaffirmed an "outperform" rating on shares of Exagen in a report on Wednesday, November 13th.
Get Our Latest Analysis on Exagen
Exagen Price Performance
Shares of Exagen stock traded down $0.05 during midday trading on Monday, hitting $3.12. 79,519 shares of the company traded hands, compared to its average volume of 248,101. The stock has a market cap of $55.03 million, a price-to-earnings ratio of -3.32 and a beta of 1.42. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The firm's fifty day moving average price is $4.02 and its 200-day moving average price is $3.10. Exagen has a 12 month low of $1.30 and a 12 month high of $6.22.
Exagen (NASDAQ:XGN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The firm had revenue of $12.51 million for the quarter, compared to analyst estimates of $13.55 million. During the same period in the previous year, the firm posted ($0.31) EPS. As a group, sell-side analysts forecast that Exagen will post -0.87 earnings per share for the current year.
Insider Transactions at Exagen
In other Exagen news, major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the company's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $3.30, for a total value of $660,000.00. Following the transaction, the insider now owns 2,108,958 shares of the company's stock, valued at $6,959,561.40. This represents a 8.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John Aballi acquired 24,305 shares of the business's stock in a transaction on Thursday, November 14th. The stock was acquired at an average cost of $2.81 per share, for a total transaction of $68,297.05. Following the transaction, the chief executive officer now directly owns 689,799 shares in the company, valued at $1,938,335.19. The trade was a 3.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 26.10% of the company's stock.
Institutional Investors Weigh In On Exagen
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC raised its stake in shares of Exagen by 49.0% in the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company's stock worth $1,651,000 after purchasing an additional 175,701 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Exagen by 93.3% during the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company's stock worth $172,000 after acquiring an additional 45,476 shares during the period. Palumbo Wealth Management LLC grew its holdings in Exagen by 14.5% during the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company's stock worth $236,000 after acquiring an additional 9,695 shares during the period. Creative Planning acquired a new stake in Exagen during the third quarter worth about $110,000. Finally, Verus Capital Partners LLC acquired a new stake in Exagen during the third quarter worth about $39,000. 75.25% of the stock is currently owned by hedge funds and other institutional investors.
Exagen Company Profile
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Featured Stories
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
